• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
AUPH

AUPH

Aurinia Pharmaceuticals Inc.

NASDAQHealthcareBiotechnologyCA

USD15.67

+0.28 (+1.82%)

Rating:A-

Company Profile

CEO

Kevin C. Tang

IPO Date

2014-09-03

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

CA

Market Metrics

Open

$15.92

Prev. Close

$15.39

Day Low

$15.50

Day High

$15.96

52W Low

$7.29

52W High

$16.88

Market Cap

$2.02B

Volume

1.65M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

37.0%

Avg Negative

12.4%

Avg Neutral

50.3%

News Feed

Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options

Zacks Investment Research·8/18/2021·↓ negative

Aurinia (AUPH) Adds Two Candidates, Boosts Immunology Pipeline

Zacks Investment Research·8/18/2021·↓ negative

Aurinia Adds Two Assets To Expand Its Immunology Pipeline

Benzinga·8/17/2021·↑ positive

Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases

Business Wire·8/17/2021·↑ positive

Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference

Business Wire·8/9/2021·↑ positive

Why Aurinia Pharmaceuticals Stock Was Surging on Friday

The Motley Fool·8/6/2021·↑ positive

AUPH Stock Price Increases Over 14% Pre-Market: Why It Happened

Pulse2·8/6/2021·↑ positive

Aurinia Pharmaceuticals Inc. (AUPH) CEO John Leonard on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/5/2021·↓ negative

Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research·8/5/2021·↑ positive

Aurinia Pharmaceuticals to Release Second Quarter 2021 Financial Results on August 5, 2021

Business Wire·7/26/2021·↓ negative